In a Jan. 11 research note, Echelon Partners analyst Douglas Loe stated his firm again has chosen Immunovaccine Inc. (IMV:TSX; IMMVF:OTCQX) as a Top Pick for the year of the clinical development stage companies in its coverage universe. This is because "an abundance of near-term data milestones will build on the firm's momentum as it enters 2018," and the company's DepoVax platform is "driving value in multiple immune therapy markets," he noted. DepoVax is a water-free lipid-based antigen delivery system used in animals and humans.
For one, Immunovaccine's lead therapeutic, DPX-Survivac, continues to advance, indicated Loe. The survivin antigen-based vaccine currently is in Phase 2 trials for the indications, ovarian cancer and diffuse large B cell lymphoma.
Recent data from the Phase 1/2 trial evaluating treatment with DPX-Survivac and Incyte's epacadostat were "encouragingly positive on measures relating to tumor-specific immune responses and impact on tumor morphology," Loe explained. Incyte, Immunovaccine's partner in the study, presented these findings in December 2017.
As for the potential of DPX-Survivac once commercially available, Loe said, "We expect DPX-Survivac to gain revenue traction up to $36.9 million in our fiscal 2022 reference year."
Also noteworthy, Immunovaccine's "profile as a cancer immune therapy developer" was bolstered when Gilead acquired the cancer immunotherapy company Kite for $11.9 billion in 2017, Loe noted. "Gilead's interest speaks to how advanced clinical activities have been in that space in recent years."
Echelon has a Speculative Buy rating and a CA$3.25 per share price target on Immunovaccine Inc., whose stock is currently trading at around CA$2.24 per share.
Read what other experts are saying about:
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Immunovaccine Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Disclosures from Echelon Wealth Partners, Immunovaccine Inc., Jan. 11, 2018
Echelon Wealth Partners compensates its Research Analysts from a variety of sources. The Research Department is a cost centre and is funded by the business activities of Echelon Wealth Partners including, Institutional Equity Sales and Trading, Retail Sales and Corporate and Investment Banking.
ANALYST CERTIFICATION: I, Douglas Loe, hereby certify that the views expressed in this report accurately reflect my personal views about the subject securities or issuers. I also certify that I have not, am not, and will not receive, directly or indirectly, compensation in exchange for expressing the specific recommendations or views in this report.
Is this an issuer related or industry related publication? Industry.
Does the Analyst or any member of the Analyst’s household have a financial interest in the securities of the subject issuer? No
Does the Analyst or household member serve as a Director or Officer or Advisory Board Member of the issuer? No
Does Echelon Wealth Partners Inc. or the Analyst have any actual material conflicts of interest with the issuer? No
Does Echelon Wealth Partners Inc. and/or one or more entities affiliated with Echelon Wealth Partners Inc. beneficially own common shares (or any other class of common equity securities) of this issuer which constitutes more than 1% of the presently issued and outstanding shares of the issuer? No
During the last 12 months, has Echelon Wealth Partners Inc. provided financial advice to and/or, either on its own or as a syndicate member, participated in a public offering, or private placement of securities of this issuer? Yes
During the last 12 months, has Echelon Wealth Partners Inc. received compensation for having provided investment banking or related services to this Issuer? Yes
Has the Analyst had an onsite visit with the Issuer within the last 12 months? No
Has the Analyst or any Partner, Director or Officer been compensated for travel expenses incurred as a result of an onsite visit with the Issuer within the last 12 months? No
Has the Analyst received any compensation from the subject company in the past 12 months? No
Is Echelon Wealth Partners Inc. a market maker in the issuer’s securities at the date of this report? No